IPP Bureau
Aurobindo Pharma Foundation distributes 15 tri motor bikes to physically challenged persons at Jadcherla, Telangana
By IPP Bureau - June 27, 2022
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
By IPP Bureau - June 27, 2022
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against omicron
By IPP Bureau - June 27, 2022
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
Novartis commits US$ 250 million to the fight against NTDs and malaria
By IPP Bureau - June 24, 2022
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Novartis receives EC approval for Tabrecta for the treatment of non-small cell lung cancer
By IPP Bureau - June 24, 2022
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Vividion Therapeutics names Aleksandra Rizo as President and Head of R&D
By IPP Bureau - June 24, 2022
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
ANI Pharmaceuticals gets FDA approval of Clorazepate Dipotassium Tablets USP
By IPP Bureau - June 24, 2022
ANI’s Clorazepate Dipotassium Tablets are the generic version of the Reference Listed Drug (RLD) Tranxene.
MEI Pharma appoints Anne Frese as Chief People Officer
By IPP Bureau - June 24, 2022
Most recently, she served as chief human resources officer at Vyripharm Enterprises.
Mandaviya chairs high level meeting to review COVID-19 status
By IPP Bureau - June 24, 2022
The Minister directed officials to continue to focus on surveillance and on Whole Genome Sequencing to scan for any possible mutation and also directed for monitoring hospitalizations due to COVID-19 and SARI/ILI cases
Silo Pharma expands license agreement and patent portfolio
By IPP Bureau - June 24, 2022
Silo enters into commercial evaluation license agreement for next generation liposomes
Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
By IPP Bureau - June 24, 2022
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Rivaroxaban approved in Japan for patients with PAD after revascularisation
By IPP Bureau - June 24, 2022
It´s the first trial to demonstrate the benefits of dual pathway inhibition
CPC Scientific announces new California peptide API manufacturing facility
By IPP Bureau - June 24, 2022
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Merck KGaA doubles HPAPI production capacity in Wisconsin
By IPP Bureau - June 24, 2022
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Menarini Group and Radius Health submit new drug application to the USFDA for Elacestrant
By IPP Bureau - June 23, 2022
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
